New life for immunotoxin cancer therapy

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1055-1058

  Hassan, Raffit ^a   Alewine, Christine ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IMMUNOTOXIN; PENTOSTATIN; RG 7787; SS 1 P; UNCLASSIFIED DRUG; BACTERIAL TOXIN; CANCER ANTIBODY; EXOTOXIN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SS1(DSFV)PE38; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; MESOTHELIOMA; MOUSE; PATHOLOGY;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL TOXINS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; EXOTOXINS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MESOTHELIOMA; MICE; PENTOSTATIN; VIRULENCE FACTORS;

EID: 84962265929     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1623     Document Type: Review

References (21)

1. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
2. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.N Eng J Med 2010;363:1812-21.
3. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
4. Wayne AS, Bhojwani D, Silverman LB, Richards K, Stetler-Stevenson M, Shah NN, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstract) 2011;118:248.
5. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-8.
6. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. Bioconjug Chem 1992;3:63-8.
7. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. ProcNatl Acad Sci USA 1992;89:5867-71.
8. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, MiettinenM, et al. Phase I study of the antimesothelin immuotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleuralmesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 2014;120: 3311-9.
9. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of Taxol and immunotoxin SS1P in tumorbearing mice. Clin Cancer Res 2006;12:4695-701.
10. Hollevoet K, Mason-Osann E, Liu X, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic anti-mesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014;13: 2040-9.
11. Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther 2014;13: 2653-61.
12. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5:2311-5.
13. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun 2015;6:6536.
14. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
15. Mossoba ME, Onda M, Taylor J, Treadwell S, Sharon E, Hassan R, et al. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res 2011;11: 3697-705.
16. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013;5: 208ra147.
17. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 2013;12:48-57.
18. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A 2012;109:11782-7.
19. Niederfellner G, Bauss F, Imhof-Jung S, Hesse F, Kronenberg S, Staak R, et al. RG7787-a novel de-immunized PE based fusion protein fo therapy of mesothelin-positive solid tumors [abstract]. In: Proceedings of the AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. Abstract nr 4510.
20. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
21. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.